Core annular flow is used to enable the subcutaneous delivery of a viscous fluid such as a protein therapeutic formulation. The high-viscosity fluid is surrounded by a low-viscosity fluid, and the low-viscosity fluid lubricates the passage of the high-viscosity fluid. This allows the use of protein formulations that have a higher concentration and a higher viscosity at comparatively reduced injection forces and reduced injection times. Several different embodiments of injection devices that provide core annular flow are described herein.

The present disclosure provides compositions including self-degrading alginate particles comprising alginate, alginate lyase, and divalent metal ions. The present disclosure also provides methods of making compositions including self-degrading alginate particles comprising alginate, alginate lyase, and divalent metal ions. The present disclosure also provides methods of inducing an embolism in a subject in thereof, and syringes containing the compositions of the present disclosure for use in the methods thereof.

A system for serially injecting liquids includes a syringe body defining a syringe proximal opening and a distal needle interface, proximal and distal stopper members, forming proximal and distal chambers. The system also includes a first liquid in the distal chamber and a second liquid in the proximal chamber, and a plunger configured to be manually manipulated to insert the proximal stopper member distally. Moreover, the system includes a needle hub assembly coupled to the syringe body, the needle assembly including a needle. The needle defines a needle interior, and distal, middle and proximal openings. The distal, middle and proximal openings are fluidly coupled through the needle interior. Manipulating the plunger member to insert the proximal stopper member initially expels the first liquid from the distal chamber, then serially expels the second liquid from the proximal chamber.

Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface (e.g., a surface of a tissue of a subject). The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage (e.g., interface with, inject into, anchor) with a surface (e.g., a surface of a tissue of a subject). In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject). In some cases, upon contact of the tissue with the tissue engaging surface of the article, the self-righting article may be configured to release one or more tissue interfacing components. In some cases, the tissue interfacing component is associated with a self-actuating component. For example, the self-righting article may comprise a self-actuating component configured, upon exposure to a fluid, to release the tissue interfacing component from the self-righting article. In some cases, the tissue interfacing component may comprise and/or be associated with the pharmaceutical agent (e.g., for delivery to a location internal to a subject).

A deformable cartridge for an injection device of an injectable solution has a cartridge body having a first containment chamber of a first component of the injectable solution, having a first compression-deformable wall, a second containment chamber of a second component of the injectable solution, having a second compression-deformable wall to allow the second component to be transferred from the second containment chamber to the first containment chamber, a separation device interposed between the first and the second containment chambers and having a device body. A fluidic communication duct is defined in the device body. The deformable cartridge assumes a first operating configuration in which the fluidic communication duct is not crossable by the second component and a second operating configuration in which the fluidic communication duct is crossable by the second component. A needle holder component is fixed to the cartridge body and fluidly connected to the first containment chamber which is interposed between the needle holder component and the separation device.

A co-reactive liquids delivery applicator, including first and second hollow cylindrical cartridges, each including a stopper at a proximal end and a sealing septum on a distal end and the cartridges containing co-reactive liquids therein, an applicator body including two adjacent chambers configured to secure the first and second cylindrical cartridges, a manifold positioned at a distal portion of the applicator body, the manifold including a pair of hollow needles extending from a proximal portion and a tip connection positioned at a distal portion thereof, and a toggle configured to advance the manifold towards the distal end of the cartridge, wherein upon advancing the manifold each hollow needle penetrates the sealing septum and establishes fluid communication with one of the liquids of the first and second cylindrical cartridges.

A drug delivery device and cartridge wherein the cartridge includes a movable use indicator that indicates whether the cartridge has been opened and/or used.

A medical device includes: a medicinal agent storage device connected to the catheter, a flow control device, and a package. The medicinal agent storage device includes a storage part and a second channel, the storage part is configured to store a medicinal agent, and wherein the second channel provides fluid communication between the storage part and the first channel. The package encloses the catheter, the medicinal agent storage device, and the flow control device in a sterilized state. In a first state, the flow control device is configured to prevent the medicinal agent from flowing from the storage part into the first channel. The flow control device is included in the catheter or included in the medicinal agent storage device.

The invention relates to a valve stopper configured to be positioned inside a barrel of an injection device for injecting a composition through a distal, including: a membrane having a proximal and distal face, the membrane being configured to separate a, distal chamber of the barrel from a proximal chamber; a lateral wall extending from the membrane to define a distal cavity, the lateral wall having a circumferential sealing surface configured to sealingly engage the inner surface of the barrel; where the proximal face presents a concave shape and the membrane includes a notch extending through the membrane between the proximal and distal face, being configured to selectively create a fluid path through the membrane from the proximal face to the distal face depending on the pressure exerted by a composition onto the proximal face of the membrane for transferring fluid only from the second chamber to the first.

Components with relatively high loading of active pharmaceutical ingredients are generally provided. In some embodiments, the component (e.g., a tissue interfacing component) comprises a solid therapeutic agent and a supporting material such that the solid therapeutic agent is present in the component in an amount of greater than or equal to 10 wt % versus the total weight of the tissue interfacing component. Such tissue-interfacing components may be useful for delivery of API doses e.g., to a subject. Advantageously, in some embodiments, the reduction of volume required to deliver the required API dose as compared to a liquid formulation permits the creation of solid needle delivery systems for a wide variety of drugs in a variety of places/tissues (e.g., tongue, GI mucosal tissue, skin) and/or reduces and/or eliminates the application of an external force in order to inject a drug solution through the small opening in the needle. In some cases, a physiologically relevant dose may be present in a single tissue interfacing component.